Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/14542

Title: A statistical approach to central monitoring of data quality in clinical trials
Authors: Venet, David
Doffagne, Erik
Burzykowski, Tomasz
Beckers, Francois
Tellier, Yves
Genevois-Marlin, Eric
Becker, Ursula
Bee, Valerie
Wilson, Veronique
Legrand, Catherine
Buyse, Marc
Issue Date: 2012
Citation: CLINICAL TRIALS, 9 (6), p. 705-713
Abstract: Background Classical monitoring approaches rely on extensive on-site visits and source data verification. These activities are associated with high cost and a limited contribution to data quality. Central statistical monitoring is of particular interest to address these shortcomings. Purpose This article outlines the principles of central statistical monitoring and the challenges of implementing it in actual trials. Methods A statistical approach to central monitoring is based on a large number of statistical tests performed on all variables collected in the database, in order to identify centers that differ from the others. The tests generate a high-dimensional matrix of p-values, which can be analyzed by statistical methods and bioinformatic tools to identify extreme centers. Results Results from actual trials are provided to illustrate typical findings that can be expected from a central statistical monitoring approach, which detects abnormal patterns that were not (or could not have been) detected by on-site monitoring. Limitations Central statistical monitoring can only address problems present in the data. Important aspects of trial conduct such as a lack of informed consent documentation, for instance, require other approaches. The results provided here are empirical examples from a limited number of studies. Conclusion Central statistical monitoring can both optimize on-site monitoring and improve data quality and as such provides a cost-effective way of meeting regulatory requirements for clinical trials. Clinical Trials 2012; 9: 705-713. http://ctj.sagepub.com
Notes: [Buyse, Marc] IDDI Inc, Houston, TX 77060 USA. [Venet, David; Doffagne, Erik; Burzykowski, Tomasz] IDDI, Louvain, Belgium. [Venet, David] Univ Libre Brussels, IRIDIA, Brussels, Belgium. [Burzykowski, Tomasz; Buyse, Marc] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BioSt, Diepenbeek, Belgium. [Beckers, Francois; Tellier, Yves] GlaxoSmithKline Biol, Wavre, Belgium. [Genevois-Marlin, Eric] Sanofi Aventis R&D Biostat & Programming, Bridgewater, NJ USA. [Becker, Ursula] F Hoffmann LaRoche Ltd, Basel, Switzerland. [Bee, Valerie; Wilson, Veronique] Translat Res Oncol TRIO, Paris, France. [Legrand, Catherine] Catholic Univ Louvain, Inst Stat Biostat & Actuarial Sci ISBA, B-1348 Louvain, Belgium.
URI: http://hdl.handle.net/1942/14542
DOI: 10.1177/1740774512447898
ISI #: 000312452600006
ISSN: 1740-7745
Category: A1
Type: Journal Contribution
Validation: ecoom, 2014
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
N/A909.2 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.